在中枢神经系统安全药理学中对稳健性的系统评估
Maria Reiber1, Helen Stirling1, Tim P Ahuis2
1Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.
British journal of pharmacology
|October 10, 2024
概括
协调欧文试验协议改善了临床前神经学药物安全性研究的数据一致性. 标准化评分减少了变异性,提高了药物开发的欧文测试的可靠性.
科学领域:
- 在临床前的药理学.
- 神经科学是一个神经科学.
- 药物安全性评估 药物安全性评估
背景情况:
- 欧文测试对于在临床前研究中评估药物诱导的神经副作用至关重要.
- 临床前数据框架的增强质量旨在改善临床前发现向临床应用的过渡.
研究的目的:
- 评估跨国研究场所的欧文试验的稳定性和场地间的变异性.
- 评估协议协调对爱尔温测试数据质量在三个不同阶段的影响.
主要方法:
- 通过腹膜内注射,NMRI小鼠接受了车载或MK-801 (0.1或0.3毫克/公斤).
- 欧文评分是在基线和注射后根据本地 (第一阶段),部分协调 (第二阶段) 和完全协调 (第三阶段) 协议收集的.
主要成果:
- 在第一阶段和第二阶段观察到大量的数据变化,现场之间的总体异质性明显.
- 欧文评分的完全协调 (第三阶段) 将整体异质性降低到功能领域内的中等水平.
- 在运动领域检测到很大的效果大小,在与治疗组和车辆进行比较时,在兴奋和自主领域有微妙到中度的影响.
结论:
- 对于MK-801等中枢神经系统活性化合物的欧文试验数据,实验室间的显著变异性需要在药物开发中仔细考虑.
- 欧文测试参数和评分方法的协调可以有效地限制变化,提高数据的稳定性.
- 与评分协调相比,环境和一般研究设计的修改对减少数据异质性的影响有限.
更多相关视频
15:05Functional Evaluation of Biological Neurotoxins in Networked Cultures of Stem Cell-derived Central Nervous System Neurons
Published on: February 5, 2015
9.3K
17:28Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
Published on: June 17, 2015
12.6K
相关概念视频
01:19Pharmacovigilance
783
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
783
01:28Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K